Back

Clinical profile, prognosis, and medical therapy of heart failure with mildly reduced ejection fraction in clinical practice

29 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Solutions across the spectrum of heart failure Heart Failure with Mid-Range Ejection Fraction (HFmrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Jason Wasfy

Massachusetts General Hospital - Harvard Medical School, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
The illusion of difference: do remodeling patterns truly distinguish HF phenotypes?
Doctor I. Jitari (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Impact of simple GDMT score on prognosis in heart failure patients with cardio-renal anemia syndrome: insights from QHEART study
Doctor M. Tokumoto (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Experimental evidence for the influence of pregnancy history on HFpEF development later in life
Doctor R. Magaye (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Prognostic value of the CONUT nutritional score in HFpEF: a large-scale cohort study evaluating inflammation-driven effect modification
Doctor J. Yang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Solutions across the spectrum of heart failure

The Event

Event poster

ESC Congress 2026

29 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population
21 May 2023
thumbnail
Congress Presentation
The impact of secondary mitral regurgitation on the prognosis of heart failure with mildly reduced ejection fraction
20 May 2025
thumbnail
Congress Presentation
Is there still a role for neurohormonal therapy in patients with STEMI and mildly reduced ejection
22 May 2023
thumbnail
Webinar
Unmet needs in HF: patients with LVEF equal or above 40%
12 December 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources